Psoriasis: IL23 Inhibitors

FDA Approves Tremfya (guselkumab) for Plaque Psoriasis (VOYAGE & NAVIGATE Trials)

The U.S. Food and Drug Administration (FDA) has approved the IL-23 inhibitor, Tremfya (guselkumab), for patients with moderate to severe plaque psoriasis.

Guselkumab tops adalimumab for psychiatric comorbidities in psoriasis (VOYAGE 2)

Treatment with guselkumab was associated with…

Tildrakizumab, an IL-23 Inhibitor, is Successful in Plaque Psoriasis

Therapeutic options for cutaneous psoriasis (and psoriatic arthritis as well) are rapidly expanding.  Lancet has published the impressive results of two phase III trials of tildrakizumab, a IgG1 antibody against interleukin 23 p19, in patients with active chronic plaque psoriasis.

Risankizumab Outperforms Humira, Stelara in Treating Plaque Psoriasis (IMMvent & UltlMMa Trials)

As AbbVie’s best-selling Humira faces oncoming biosimilar competition, the drug maker is developing a new innovator product that could help it retain a hold on the…

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Original Article from The New England Journal of Medicine — Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

No Comments Yet.

Leave a comment